Esperion Therapeutics, Inc. $ESPR Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC decreased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 36.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 74,786 shares of the biopharmaceutical company’s stock after selling 42,946 shares during the period. MetLife Investment Management LLC’s holdings in Esperion Therapeutics were worth $108,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. CW Advisors LLC acquired a new stake in shares of Esperion Therapeutics during the first quarter worth about $74,000. Summit Financial LLC boosted its stake in shares of Esperion Therapeutics by 40.1% during the first quarter. Summit Financial LLC now owns 65,194 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 18,666 shares during the period. Wellington Management Group LLP boosted its stake in shares of Esperion Therapeutics by 36.0% during the first quarter. Wellington Management Group LLP now owns 761,980 shares of the biopharmaceutical company’s stock worth $1,097,000 after buying an additional 201,704 shares during the period. Meridian Wealth Management LLC acquired a new stake in shares of Esperion Therapeutics during the first quarter worth about $29,000. Finally, Nuveen LLC acquired a new stake in shares of Esperion Therapeutics during the first quarter worth about $4,446,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Up 2.4%

Esperion Therapeutics stock opened at $2.60 on Thursday. The firm’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $1.37. Esperion Therapeutics, Inc. has a 52 week low of $0.69 and a 52 week high of $3.94. The firm has a market capitalization of $524.21 million, a PE ratio of -5.31, a P/E/G ratio of 57.05 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.15. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. The business had revenue of $82.39 million during the quarter, compared to analysts’ expectations of $62.55 million. On average, research analysts expect that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

ESPR has been the subject of several analyst reports. Wall Street Zen cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 25th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.